PURPOSE: A population-based cohort study of soft tissue sarcoma of the extremities (STSE) in Ontario, Canada was conducted using linked administrative databases. METHODS AND MATERIALS: Electronic administrative databases were linked from the Ontario Cancer Registry, the Canadian Institute for Health Information, and Radiation Oncology Research Unit database of radiation therapy (RT) records. RESULTS: The definitive surgery was amputation for 6.0%, resection for 60.9%, biopsy for 7.5%; the remainder had no surgical record. Adjuvant RT was administered to 40.2% of cases. Among cases initially treated by surgical resection, 2.0% later underwent amputation and 9.5% underwent further resection during follow-up. The adjusted odds ratio (OR) for amputation as definitive surgery was 2.3 (1.19, 4.45) in eastern Ontario relative to Toronto. The likelihood of adjuvant RT among those not registered at a cancer centre within 3 months of diagnosis was decreased (OR = 0.20 (95% CI (0.13, 0.30)) relative to those registered. The adjusted relative risk of amputation at any time following diagnosis was 3.48 (95% CI (1.63, 7.46)) among cases not attending a cancer centre. The adjusted relative risk of death was 1.4; 95% CI (1.1, 1.7) among those not attending a cancer centre. CONCLUSIONS: Cases not seen at a multidisciplinary cancer centre within 3 months following diagnosis of STSE have an increased relative risk for amputation at any time, and for death due to any cause. Many hypotheses for further study are suggested by the results of this analysis.
PURPOSE: A population-based cohort study of soft tissue sarcoma of the extremities (STSE) in Ontario, Canada was conducted using linked administrative databases. METHODS AND MATERIALS: Electronic administrative databases were linked from the Ontario Cancer Registry, the Canadian Institute for Health Information, and Radiation Oncology Research Unit database of radiation therapy (RT) records. RESULTS: The definitive surgery was amputation for 6.0%, resection for 60.9%, biopsy for 7.5%; the remainder had no surgical record. Adjuvant RT was administered to 40.2% of cases. Among cases initially treated by surgical resection, 2.0% later underwent amputation and 9.5% underwent further resection during follow-up. The adjusted odds ratio (OR) for amputation as definitive surgery was 2.3 (1.19, 4.45) in eastern Ontario relative to Toronto. The likelihood of adjuvant RT among those not registered at a cancer centre within 3 months of diagnosis was decreased (OR = 0.20 (95% CI (0.13, 0.30)) relative to those registered. The adjusted relative risk of amputation at any time following diagnosis was 3.48 (95% CI (1.63, 7.46)) among cases not attending a cancer centre. The adjusted relative risk of death was 1.4; 95% CI (1.1, 1.7) among those not attending a cancer centre. CONCLUSIONS: Cases not seen at a multidisciplinary cancer centre within 3 months following diagnosis of STSE have an increased relative risk for amputation at any time, and for death due to any cause. Many hypotheses for further study are suggested by the results of this analysis.
Authors: B O'Sullivan; J Wylie; C Catton; E Gutierrez; C J Swallow; J Wunder; P Gullane; P Neligan; R Bell Journal: Semin Radiat Oncol Date: 1999-10 Impact factor: 5.934
Authors: E F Gaffney; P A Dervan; M M McCabe; K Sheahan; E W Kay; M Leader; J Doyle; P A Daly; J J Fennelly; D N Carney Journal: Ir J Med Sci Date: 1994-05 Impact factor: 1.568
Authors: R S Bell; B O'Sullivan; F F Liu; J Powell; F Langer; V L Fornasier; B Cummings; P N Miceli; N Hawkins; I Quirt Journal: J Bone Joint Surg Am Date: 1989-03 Impact factor: 5.284
Authors: A N Wilson; A Davis; R S Bell; B O'Sullivan; C Catton; F Madadi; R Kandel; V L Fornasier Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: C E Danjoux; R D Jenkin; J McLaughlin; L Grimard; L E Gaspar; A R Dar; B Fisher; A C Whitton; V Kraus; C D Springer Journal: Med Pediatr Oncol Date: 1996-01
Authors: Javier Martin-Broto; Nadia Hindi; Josefina Cruz; Javier Martinez-Trufero; Claudia Valverde; Luis M De Sande; Angeles Sala; Lorena Bellido; Ana De Juan; Jordi Rubió-Casadevall; Roberto Diaz-Beveridge; Ricardo Cubedo; Oscar Tendero; Diego Salinas; Isidro Gracia; Rafael Ramos; Silvia Baguè; Antonio Gutierrez; José Duran-Moreno; Antonio Lopez-Pousa Journal: Oncologist Date: 2018-11-08
Authors: Tobias M Ballhause; Sebastian Weiss; Alonja Reiter; Karl-Heinz Frosch; Andreas M Luebke; Peter Bannas; Carsten W Schlickewei; Matthias H Priemel Journal: World J Surg Oncol Date: 2022-06-08 Impact factor: 3.253
Authors: Tobias M Ballhause; Alexander Korthaus; Martin Jahnke; Karl-Heinz Frosch; Jin Yamamura; Tobias Dust; Carsten W Schlickewei; Matthias H Priemel Journal: Diagnostics (Basel) Date: 2022-05-21
Authors: Sebastian Weiss; Alexander Korthaus; Nora Baumann; Jin Yamamura; Alexander S Spiro; Andreas M Lübke; Karl-Heinz Frosch; Carsten Schlickewei; Matthias Priemel Journal: Diagnostics (Basel) Date: 2021-04-14
Authors: Tobias M Ballhause; Alonja Reiter; Alexander Korthaus; Karl-Heinz Frosch; Carsten W Schlickewei; Matthias H Priemel Journal: BMC Health Serv Res Date: 2022-04-06 Impact factor: 2.655